WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bayer

The Bayer GroupBayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.

www.bayer.com.

Bayer RSS Channel

Filters
List of articles in category Bayer
Title Published Date
Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent 16 May 2008
International study to evaluate efficacy and safety in treating a leading cause of blindness 09 May 2008
Bayer Schering Pharma to market new low-dose oral contraceptive YAZ® in Europe 07 May 2008
Follicular lymphoma: EU approval for Zevalin® as First-Line Consolidation Treatment 28 April 2008
Bayer Challenges Watson and Sandoz U.S. ANDA Filings on Yasmin® 22 April 2008
Bayer donates €250,000 for patients with hemophilia 19 April 2008
Bayer appeals invalidity ruling on its Yasmin® Patent 01 April 2008
Levitra® - Therapy suitable for men with High Cholesterol 26 March 2008
Zevalin® Receives Positive CHMP Opinion in Europe for First-Line Consolidation Treatment 21 March 2008
Court decides against Bayer'€™s Yasmin® patent 04 March 2008
The Bayer Group once again considerably improved its sales and earnings in 2007 28 February 2008
Bayer and Onyx Provide Update on Phase III Trial of Nexavar® 19 February 2008
Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 11 February 2008
Expanded Labeling for MabCampath® in Europe 04 January 2008
Pivotal Phase III Data Show Superior Efficacy of Rivaroxaban over Enoxaparin 10 December 2007
Bayer Schering Pharma paves the way to the next important oral contraceptive milestone 04 December 2007
New Phase III Trial Results for Rivaroxaban 12 November 2007
Bayer Temporarily Suspends Global Trasylol® Marketing 05 November 2007
Nexavar® Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe 31 October 2007
Bayer Issues Additional Guidance to Physicians on Trasylol® 26 October 2007
  • Start
  • Prev
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
  • End

Business & Industry

  • Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
  • Bayer transforms pharma business through breakthrough innovation in healthcare
  • Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate
  • An in vitro study shows Pfizer-BioNTech COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with a mutation associated with rapid transmission
  • European Commission authorizes COVID-19 vaccine Moderna in Europe

Research & Development

  • New England Journal of Medicine publishes COVID-19 treatment trial results
  • Scientists identify 'immune cop' that detects SARS-CoV-2
  • New findings help explain how COVID-19 overpowers the immune system
  • New virtual screening strategy identifies existing drug that inhibits COVID-19 virus
  • Sustained cellular immune dysregulation in individuals recovering from COVID-19
  • How SARS-CoV-2 interacts with cells
  • Neutralizing antibodies protect against severe COVID-19

Conferences & Events

  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production
  • Wearable Injectors and Connected Devices Conference 2020

Regulatory Affairs

  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  • FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
  • EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2
  1. You are here:  
  2. Home
  3. Bayer
  4. Bayer transforms pharma business through breakthrough innovation in healthcare

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.